Philip Agop Philip

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 24 papers. Top paper: “Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome”.

Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3920

N/A

0DataRank · unranked

13 citations

Peter C. Enzinger, Andrew Ko, Allyson J. Ocean, Philip Agop Philip, Prashant V. Thakkar +20 more

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4504

N/A

0DataRank · unranked

115 citations

Mai T. Duong, Syed A. Ahmad, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam +7 more

Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps447

N/A

0DataRank · unranked

13 citations

Katherine A. Guthrie, Michael J. Pishvaian, Andrew M. Lowy, E. Gabriela Chiorean, Mai T. Duong +3 more

Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.419

N/A

0DataRank · unranked

2 citations

Mai T. Duong, Renee B. Chang, Yuqing Xue, Devora Delman, Ignacio Garrido‐Laguna +15 more

Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4131

N/A

0DataRank · unranked

0 citations

Mai T. Duong, Robert D. Boutin, Leon Lenchik, Jiyoon Kim, Namita Gandhi +11 more

Does adjuvant chemoradiation benefit patients with lymph node-positive biliary tract cancer? A secondary analysis of SWOG S0809.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4104

N/A

0DataRank · unranked

0 citations

Mai T. Duong, David P. Horowitz, Katherine A. Guthrie, Edgar Ben‐Josef, Anthony B. El-Khoueiry +5 more

Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps515

N/A

0DataRank · unranked

9 citations

Katherine A. Guthrie, Syed A. Ahmad, M. Kay Washington, Brian Hemendra Ramnaraign, Nitya Raj +8 more

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps212

N/A

0DataRank · unranked

7 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +8 more

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3643

N/A

0DataRank · unranked

3 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +9 more

Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps643

N/A

0DataRank · unranked

2 citations

Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Shay Bellasea +2 more

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.lba490

N/A

0DataRank · unranked

99 citations

Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin +15 more

Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3640

N/A

0DataRank · unranked

21 citations

Arvind Dasari, Qian Shi, Julio García‐Aguilar, Hanna K. Sanoff, Thomas J. George +13 more

APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps763

N/A

0DataRank · unranked

8 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps265

N/A

0DataRank · unranked

8 citations

Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zishuo Ian Hu +6 more

A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.140

N/A

0DataRank · unranked

7 citations

Katherine A. Guthrie, Scott Kopetz, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih +15 more

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4198

N/A

0DataRank · unranked

6 citations

Katherine A. Guthrie, Michael J. Pishvaian, Kim Anna Reiss, Andrew M. Lowy, Davendra Sohal +7 more

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4202

N/A

0DataRank · unranked

3 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps784

N/A

0DataRank · unranked

1 citations

Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby +7 more

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3634

N/A

0DataRank · unranked

1 citations

Yu Guan, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Sahin +10 more

NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps260

N/A

0DataRank · unranked

0 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +10 more

Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma

Gastroenterology(2024)10.1053/j.gastro.2024.01.013

N/A

0DataRank · unranked

18 citations

Sarah Colby, Ignacio Garrido‐Laguna, Yuqing Xue, Renee B. Chang, Devora Delman +14 more

XPO1 inhibition as a clinically viable strategy to enhance durability of response to KRAS G12D inhibitor in pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.4_suppl.736

N/A

0DataRank · unranked

0 citations

Husain Yar Khan, Amro Aboukameel, Sahar F. Bannoura, Khalil Choucair, Eliza W. Beal +9 more

Trials in progress: Alliance A022104/NRG-GI010—A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC; the Janus Rectal Cancer trial).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.tps3650

N/A

0DataRank · unranked

0 citations

Qian Shi, Arvind Dasari, Julio García‐Aguilar, Hanna K. Sanoff, Thomas J. George +15 more

Multi-Omics Profiling Reveals the Interplay Between Genomic Instability and Microenvironmental Remodeling in Pancreatic Neuroendocrine Tumors

Preprints.org(2025)10.20944/preprints202509.0362.v1

N/A

0DataRank · unranked

0 citations

Yingnan Zhang, Philip Agop Philip, Herbert Chen, Bassel F. El‐Rayes, Asfar S. Azmi +2 more